ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of AUD 44.79 billion. The enterprise value is 44.00 billion.

Market Cap	44.79B
Enterprise Value	44.00B

Important Dates

The next confirmed earnings date is Thursday, April 30, 2026.

Earnings Date	Apr 30, 2026
Ex-Dividend Date	Feb 11, 2026

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.43%
Shares Change (QoQ)	-0.36%
Owned by Insiders (%)	0.52%
Owned by Institutions (%)	76.01%
Float	144.15M

Valuation Ratios

The trailing PE ratio is 20.11 and the forward PE ratio is 19.00.

PE Ratio	20.11
Forward PE	19.00
PS Ratio	5.53
PB Ratio	4.73
P/TBV Ratio	10.50
P/FCF Ratio	16.68
P/OCF Ratio	15.61
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.30, with an EV/FCF ratio of 16.38.

EV / Earnings	19.75
EV / Sales	5.86
EV / EBITDA	15.30
EV / EBIT	17.10
EV / FCF	16.38

Financial Position

The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.13.

Current Ratio	3.06
Quick Ratio	1.97
Debt / Equity	0.13
Debt / EBITDA	0.41
Debt / FCF	0.47
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 25.68% and return on invested capital (ROIC) is 26.60%.

Return on Equity (ROE)	25.68%
Return on Assets (ROA)	14.75%
Return on Invested Capital (ROIC)	26.60%
Return on Capital Employed (ROCE)	25.44%
Weighted Average Cost of Capital (WACC)	9.10%
Revenue Per Employee	763,477
Profits Per Employee	210,153
Employee Count	10,600
Asset Turnover	0.69
Inventory Turnover	2.15

Taxes

In the past 12 months, ResMed has paid 498.95 million in taxes.

Income Tax	498.95M
Effective Tax Rate	18.30%

Stock Price Statistics

The stock price has decreased by -14.94% in the last 52 weeks. The beta is 0.93, so ResMed's price volatility has been similar to the market average.

Beta (5Y)	0.93
52-Week Price Change	-14.94%
50-Day Moving Average	33.46
200-Day Moving Average	38.25
Relative Strength Index (RSI)	34.86
Average Volume (20 Days)	1,097,834

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	10.27

Income Statement

In the last 12 months, ResMed had revenue of AUD 8.09 billion and earned 2.23 billion in profits. Earnings per share was 15.16.

Revenue	8.09B
Gross Profit	4.98B
Operating Income	2.77B
Pretax Income	2.73B
Net Income	2.23B
EBITDA	3.04B
EBIT	2.77B
Earnings Per Share (EPS)	15.16

Balance Sheet

The company has 2.12 billion in cash and 1.27 billion in debt, giving a net cash position of 853.57 million.

Cash & Cash Equivalents	2.12B
Total Debt	1.27B
Net Cash	853.57M
Net Cash Per Share	n/a
Equity (Book Value)	9.48B
Book Value Per Share	65.06
Working Capital	3.85B

Cash Flow

In the last 12 months, operating cash flow was 2.87 billion and capital expenditures -184.23 million, giving a free cash flow of 2.69 billion.

Operating Cash Flow	2.87B
Capital Expenditures	-184.23M
Depreciation & Amortization	250.52M
Net Borrowing	-13.96M
Free Cash Flow	2.69B
FCF Per Share	n/a

Margins

Gross margin is 61.47%, with operating and profit margins of 34.19% and 27.53%.

Gross Margin	61.47%
Operating Margin	34.19%
Pretax Margin	33.69%
Profit Margin	27.53%
EBITDA Margin	37.51%
EBIT Margin	34.19%
FCF Margin	33.19%

Dividends & Yields

This stock pays an annual dividend of 0.35, which amounts to a dividend yield of 1.14%.

Dividend Per Share	0.35
Dividend Yield	1.14%
Dividend Growth (YoY)	14.59%
Years of Dividend Growth	1
Payout Ratio	2.31%
Buyback Yield	0.43%
Shareholder Yield	1.57%
Earnings Yield	4.97%
FCF Yield	6.00%

Dividend Details

Stock Splits

The last stock split was on August 12, 2010. It was a forward split with a ratio of 2.

Last Split Date	Aug 12, 2010
Split Type	Forward
Split Ratio	2

Scores

ResMed has an Altman Z-Score of 12.89 and a Piotroski F-Score of 6.

Altman Z-Score	12.89
Piotroski F-Score	6